Male Infertility Global Market Report 2025

The male infertility market size has grown strongly in recent years. It will grow from $3.59 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to increased awareness of male reproductive health, a rise in lifestyle-related disorders affecting fertility, greater adoption of assisted reproductive technologies (ART), the expansion of fertility clinics and diagnostic centers, and technological advancements in semen analysis.

The male infertility market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period is driven by an increasing focus on genetic and epigenetic contributors to infertility, growing demand for personalized treatment approaches, the expansion of medical tourism for fertility services, innovations in sperm retrieval and preservation methods, and the integration of telehealth in fertility consultations. Key trends expected include the broader use of genetic testing for infertility diagnosis, advancements in retrieval techniques such as micro-TESE, increasing preference for non-invasive treatment options, development of personalized fertility plans for men, and the emerging use of stem cell therapy to restore spermatogenesis.

The rising levels of stress are expected to drive the growth of the male infertility market in the coming years. Stress refers to the emotional, physical, or mental strain experienced in response to challenging situations or pressures. Increased stress levels are largely due to escalating work demands, which lead to burnout, disrupt mental health, and impair work-life balance. High stress can interfere with hormone regulation, reduce sperm quality, and impact sexual function, all of which contribute to male infertility. Chronic stress disrupts the balance of cortisol and testosterone, further increasing the risk of infertility. For example, in May 2024, the American Psychiatric Association reported that 43% of adults in the U.S. felt more anxious in 2024, compared to 37% in 2023 and 32% in 2022, indicating a steady rise in anxiety levels. As a result, the increasing stress levels are playing a significant role in the growth of the male infertility market.

Key companies in the male infertility market are leveraging strategic partnerships to enhance access to advanced fertility treatments across global markets. Strategic partnerships involve collaborations between organizations to pool resources and expertise, ultimately driving innovation, expanding market presence, and enhancing research and development efforts. For example, in June 2024, Ferring Pharmaceuticals, a Switzerland-based pharmaceutical company, formed a partnership with Posterity Health, a U.S.-based male fertility clinic. Together, they introduced a male fertility program on Ferring's Fertility Out Loud platform. This program provides men with a confidential online assessment and educational resources created by reproductive urologists to better understand their fertility status. By reducing the stigma surrounding male infertility, which contributes to about 50% of infertility cases, the initiative aims to empower men to take early action, potentially improving their chances of parenthood by addressing fertility issues sooner through digital tools and telehealth.

In June 2024, CooperSurgical, a U.S.-based fertility and women’s healthcare company, acquired ZyMōt Fertility for an undisclosed sum. This acquisition aims to strengthen CooperSurgical’s ART (assisted reproductive technology) portfolio by adding a patented sperm separation device that enhances motile sperm selection, improving pregnancy outcomes. ZyMōt Fertility is known for its advanced sperm separation technology, which plays a critical role in treating male infertility.

Major players in the male infertility market are Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., NYU Langone Hospitals, Sun Pharmaceutical Industries Ltd., Cipla Limited, Ferring Pharmaceuticals, Fortis Healthcare, Vitrolife, Max Healthcare, CinnaGen Co., Aytu BioScience Inc., Zydus Hospitals and Healthcare Research Private Limited, Apricus Biosciences Inc., SCSA Diagnostics Inc., Andrology Solutions, Halotech DNA, Indira IVF, Conduit Pharmaceuticals, Shree IVF Clinics.

North America was the largest region in the male infertility market in 2024. The regions covered in male infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the male infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Male infertility refers to a man's inability to achieve pregnancy with a fertile female partner after one year of regular, unprotected intercourse. This condition is commonly caused by issues related to sperm quantity or quality and may result from structural abnormalities, hormonal imbalances, genetic disorders, or other health-related factors.

The primary treatment types for male infertility include medication, surgery, and assisted reproductive technology. Medications are used to address hormonal imbalances or stimulate sperm production, while avoiding synthetic testosterone due to its suppressive effect on sperm. Diagnosis involves several test methods, such as sperm agglutination, DNA fragmentation analysis, oxidative stress testing, computer-assisted semen analysis, and sperm penetration assays. These treatments are distributed through hospital pharmacies, drugstores, and online pharmacies, and are utilized by hospitals and clinics, fertility centers, research institutions, and other healthcare providers.

The male infertility market research report is one of a series of new reports that provides male infertility market statistics, including the male infertility industry global market size, regional shares, competitors with the male infertility market share, detailed male infertility market segments, market trends, opportunities, and any further data you may need to thrive in the male infertility industry. This male infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The male infertility market consists of revenues earned by entities by providing services such as diagnostic testing, counseling and lifestyle guidance, and hormonal therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The male infertility market includes sales of fertility supplements, semen analysis kits, surgical devices, and lifestyle and sperm health devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.